• Mechanisms and Pharmaceutical RCTs

  • Jan 17 2025
  • Length: 17 mins
  • Podcast

Mechanisms and Pharmaceutical RCTs

Listen for free

View show details

  • Summary

  • In this episode, mechanisms and research are discussed. The question, ‘if we have a randomized control trial (RCT), can we do without knowledge of a mechanism?’ is answered. It is held that mechanisms do make a substantive difference to the optimization of a RCT. This is defended through two cases — the failed Duchenne Muscular Dystrophy Phase 3 trials in 2024 ran by Sarepta Therapeutics and Pfizer and the daptomycin 2005 trial to test its efficacy in patients Gram-positive community acquired pneumonia. Nancy Cartwright’s INUS contributors are put forth as a potential objection. However, an as-complete-as-possible concept of mechanistic understanding and reasoning is advocated for ultimately.
    Show More Show Less
Show More Show Less

What listeners say about Mechanisms and Pharmaceutical RCTs

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available